About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Research Shows Functional Characteristics of Antitumor T Cells Change With Increasing Time After Therapeutic Transfer

by Kathy Jones on March 24, 2013 at 5:16 PM
Font : A-A+

 Research Shows Functional Characteristics of Antitumor T Cells Change With Increasing Time After Therapeutic Transfer

The way in which the functionality of genetically engineered T cells administered therapeutically to patients with melanoma changed over time has been characterized by scientists.

The data, which are published in Cancer Discovery, a journal of the American Association for Cancer Research, highlight the need for new strategies to sustain antitumor T cell functionality to increase the effectiveness of this immunotherapeutic approach.

Advertisement

Early clinical research has indicated that cell-based immunotherapies for cancer, in particular melanoma, have potential because patients treated with antitumor T cells frequently have an initial tumor response; however, those responses are often transient.

"The cell-based immunotherapy we utilized was that of genetically engineered T cells," said James R. Heath, Ph.D., Elizabeth W. Gilloon Professor of Chemistry at the California Institute of Technology in Pasadena, Calif. "This approach is the most widely applicable way to generate large numbers of highly functional antitumor T cells."
Advertisement

Different T cell functions are associated with distinct proteins. Heath and colleagues took a closer look at how genetically engineered T cells functioned or failed after being transferred into patients. To do this, they used a recently developed, multiplexed technology that gave them a high-resolution view of which function-associated proteins individual cells expressed.

The researchers analyzed T cells isolated from blood samples taken from three patients with melanoma at several time points after treatment with genetically engineered antimelanoma T cells. Each of the patients from whom samples were taken had exhibited a different level of response to the immunotherapy.

The most highly functioning genetically engineered antimelanoma T cells made up about 10 percent of the total population of transferred T cells.

"However, they dominated the immune response," Heath said. "In other words, 10 percent of the cells are putting out 100 times more protein than the other cells."

Although these highly functioning genetically engineered T cells had high tumor-killing capabilities when a patient first received them, those capabilities disappeared within two to three weeks.

"The genetically engineered T cells did recover their high functional capacity, but those functions no longer included tumor-killing," Heath said. "However, there was another population of T cells that emerged at around one month that did exhibit tumor-killing characteristics."

These new T cells appeared to be a byproduct, through a process known as epitope spreading, of the original genetically engineered, tumor-killing T cells the patient received, Heath explained. The researchers also discovered one potential cause for the transient response to T cell therapy. Results showed that as the patient's own immune system recovered, after its initial depletion prior to therapy, those recovering T cells appeared to inhibit the antitumor immune response.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Surgical Treatment 

Recommended Reading
Stem Cells - Fundamentals
Encyclopedia section of medindia gives general info about Stem Cells...
Stem Cells - Cord Blood
Encyclopedia section of medindia gives general info about Cord Blood...
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use